Compounding Pharmacy · Palm Harbor, FL · 503A
Promise Pharmacy Review
Promise Pharmacy is a LegitScript-certified 503A compounding pharmacy headquartered in Palm Harbor, Florida that compounds patient-specific semaglutide and tirzepatide (GLP-1) for clinics and providers. It follows USP 795/797/800 standards, performs third-party potency and sterility testing on GLP-1 batches with Certificate of Analysis documentation, and is licensed by the Florida Board of Pharmacy as a nonresident compounding pharmacy serving multiple Florida markets. Note: routine 503A compounding of GLP-1s that copy commercially available products is restricted now that the FDA shortages are resolved.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
About this pharmacy
Promise Pharmacy is a LegitScript-certified 503A compounding pharmacy headquartered in Palm Harbor, Florida that compounds patient-specific semaglutide and tirzepatide (GLP-1) for clinics and providers. It follows USP 795/797/800 standards, performs third-party potency and sterility testing on GLP-1 batches with Certificate of Analysis documentation, and is licensed by the Florida Board of Pharmacy as a nonresident compounding pharmacy serving multiple Florida markets. Note: routine 503A compounding of GLP-1s that copy commercially available products is restricted now that the FDA shortages are resolved.
Certifications & Compliance
All sterile compounding pharmacies in the United States are required to follow United States Pharmacopeia General Chapter <797> sterile compounding standards[4], with finished preparations evaluated against USP <71> sterility testing[5] and USP <85> bacterial endotoxin testing[6] as appropriate for the product type.
Drugs Produced
Compounding pharmacies' ability to produce semaglutide or tirzepatide depends on the FDA Drug Shortage List status for each reference product; compounding eligibility can change when a drug moves on or off the shortage list[7].
States Licensed (0)
Regulatory Actions
Weight Loss Rankings Score Breakdown
Scores are independently researched. See our methodology for details.
Medium confidence · Last verified 2026-06-04 via manual · How we verify provider data
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- 503B outsourcing facility · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources & methodology — as of June 2026
- 1.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 2.FDA — 503B Outsourcing Facility Registration and Requirements— U.S. Food & Drug Administration.
- 3.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 4.USP General Chapter <797> — Pharmaceutical Compounding: Sterile Preparations— United States Pharmacopeia.
- 5.USP General Chapter <71> — Sterility Tests— United States Pharmacopeia.
- 6.USP General Chapter <85> — Bacterial Endotoxins Test— United States Pharmacopeia.
- 7.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.